Journal article
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
K Basile, RJ Rockett, K McPhie, M Fennell, J Johnson-Mackinnon, JE Agius, W Fong, H Rahman, D Ko, L Donavan, L Hueston, C Lam, A Arnott, SCA Chen, S Maddocks, MV O’Sullivan, DE Dwyer, V Sintchenko, J Kok
Viruses | Published : 2022
DOI: 10.3390/v14092023
Abstract
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fou..
View full abstractGrants
Awarded by National Health and Medical Research Council